Curetis Announces Participation in Major Investor and Scientific Conferences in the Second Quarter 2017
(Thomson Reuters ONE) -
Curetis /
Curetis Announces Participation in Major Investor and Scientific Conferences in
the Second Quarter 2017
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Curetis Announces Participation in Major Investor and Scientific Conferences in
the Second Quarter 2017
Amsterdam, the Netherlands, and Holzgerlingen, Germany, March 29, 2017 --
Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a
developer of next-level molecular diagnostic solutions, today announced that the
Company will attend several major industry conferences in the second quarter of
2017. The respective presentations will be made available on the company's
website.
April:
10th Kempen Life Science Day, April 19, 2017 - Amsterdam, The Netherlands:
company presentation and one-on-one meetings.
27th European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID), April 22-25, 2017 - Vienna, Austria: exhibition booth in Hall B, booth
20; sponsored symposium "Detect to cure - superbugs in various healthcare
settings. Diagnostic approaches to win the challenge", Saturday, April
22, 01:30pm CET, Hall E.
May:
ATS International Conference, May 19-24, 2017 - Washington DC, USA: exhibition
booth 1206 and KOL meetings.
Donau Invest GmbH / Advantage Strategy & Finance - Family Office Pharma &
Biotech Day, May 31, 2017 - Vienna, Austria: company presentation and Q&A
session.
June:
ASM Microbe 2017, June 1-5, 2017 - New Orleans, LA, USA: exhibition booth 2941
and oral presentation of Unyvero LRT clinical trial data.
goetzpartners Healthcare Day, June 29, 2017 - London, UK: one-on-one meetings
and panel discussion.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million.
Furthermore, Curetis has entered into a debt financing facility with EIB for up
to EUR 25 million. The company is based in Holzgerlingen near Stuttgart,
Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies,
and has entered into several international distribution agreements covering many
countries across Europe, the Middle East and Asia.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info((at))akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
Curetis_Logo:
http://hugin.info/171382/R/2091648/790359.jpg
20170329_Curetis_PR_EN:
http://hugin.info/171382/R/2091648/790358.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Curetis via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 29.03.2017 - 08:24 Uhr
Sprache: Deutsch
News-ID 533085
Anzahl Zeichen: 5906
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 143 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis Announces Participation in Major Investor and Scientific Conferences in the Second Quarter 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
